172 related articles for article (PubMed ID: 30850565)
1. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer.
Chang J; Tran J; Kamel D; Basu A
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30850565
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
Martins Machado C; Almeida Santos L; Barroso A; Oliveira MJ
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466960
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.
Kajal S; Gupta P; Ahmed A; Gupta A
Drug Discov Ther; 2021 Sep; 15(4):218-221. PubMed ID: 34456195
[TBL] [Abstract][Full Text] [Related]
6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
7. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.
Antoniou S; Bazazo G; Röckl L; Papadakis M; Berg C
BMC Endocr Disord; 2021 Sep; 21(1):191. PubMed ID: 34544399
[TBL] [Abstract][Full Text] [Related]
8. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
[No Abstract] [Full Text] [Related]
10. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Ansorge C; Seufert J; Meiss F; von Bubnoff D
J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
[No Abstract] [Full Text] [Related]
11. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
[TBL] [Abstract][Full Text] [Related]
12. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
[TBL] [Abstract][Full Text] [Related]
13. Unusual presentation of hypophysitis preceding an empty sella in a 75-year-old woman.
Klein J; Fehm HL
Neuro Endocrinol Lett; 2005 Dec; 26(6):757-8. PubMed ID: 16380671
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced adrenalitis.
Iqbal I; Khan MAA; Ullah W; Nabwani D
BMJ Case Rep; 2019 Dec; 12(11):. PubMed ID: 31791986
[TBL] [Abstract][Full Text] [Related]
15. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
16. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
Takaya K; Sonoda M; Fuchigami A; Hiyoshi T
Intern Med; 2017 Sep; 56(18):2463-2469. PubMed ID: 28824067
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy-induced autoimmune hypophysitis.
Valecha G; Pant M; Ibrahim U; Atallah JP
J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
[TBL] [Abstract][Full Text] [Related]
19. [Muscle weakness as first manifestation of panhypopituitarism secondary to empty sella syndrome].
Paz Flores C; Rosales Carballa J; Blanco Loberías J
An Med Interna; 2008 Jun; 25(6):309-11. PubMed ID: 19295984
[No Abstract] [Full Text] [Related]
20. Case of hypophysitis caused by nivolumab.
Ishikawa M; Oashi K
J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
